Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The company plans to submit the vaccine for regulatory review
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The trial will enroll up to 42 patients in Finland across four cohorts
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
